Phase I single ascending dose trial of deuterium-modified ivacaftor for the treatment of cystic fibrosis.

Trial Profile

Phase I single ascending dose trial of deuterium-modified ivacaftor for the treatment of cystic fibrosis.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2016

At a glance

  • Drugs Ivacaftor deuterated (Primary) ; Ivacaftor
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Apr 2016 Results published in Concert Pharmaceuticals media release.
    • 08 Oct 2015 Results published in a Concert Pharmaceuticals media release.
    • 22 Sep 2015 The data from this trial will be presented in the poster session at the North American Cystic Fibrosis Conference, according to a Concert Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top